Englander Institute for Precision Medicine

Publications

Found 7 results
Author Title Type [ Year(Asc)]
Filters: Author is Sridhar, Srikala S  [Clear All Filters]
2024
Sridhar SS, Powles T, Durán MÁCliment, Park SHoon, Massari F, Thiery-Vuillemin A, Valderrama BP, Ullén A, Tsuchiya N, Aragon-Ching JB et al..  2024.  Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.. Eur Urol. 85(2):154-163.
2023
Powles T, Park SHoon, Caserta C, Valderrama BP, Gurney H, Ullén A, Loriot Y, Sridhar SS, Sternberg CN, Bellmunt J et al..  2023.  Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.. J Clin Oncol. 41(19):3486-3492.
Grivas P, Park SHoon, Voog E, Caserta C, Gurney H, Bellmunt J, Kalofonos H, Ullén A, Loriot Y, Sridhar SS et al..  2023.  Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.. Eur Urol. 84(1):95-108.
2022
Powles T, Park SHoon, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovic S, Demey W, Ullén A et al..  2022.  Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer.. Future Oncol. 18(19):2361-2371.
2021
Grivas P, Agarwal N, Pal S, Kalebasty ARezazadeh, Sridhar SS, Smith J, Devgan G, Sternberg CN, Bellmunt J.  2021.  Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.. Cancer Treat Rev. 97:102187.
Powles T, Sridhar SS, Loriot Y, Bellmunt J, Mu XJasmine, Ching KA, Pu J, Sternberg CN, Petrylak DP, Tambaro R et al..  2021.  Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial.. Nat Med. 27(12):2200-2211.
2019
Pederzoli F, Bandini M, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN et al..  2019.  Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect.. Eur Urol. 76(4):425-429.